No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naïve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies

D Wyles, A Thompson, E Lawitz, B Willems, EJ Gane, E Svarovskaia, H Dvory-Sobol, R Martin, G Camus, BP Doehle, LM Stamm, RH Hyland, DM Brainard, HM Mo, T Asselah, I Jacobson, GR Foster, S Roberts